This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| RECOVERY (clinical trial) | |
|---|---|
| Name | RECOVERY |
| Status | Completed (primary analyses) |
| Sponsor | University of Oxford |
| Location | United Kingdom |
| Phase | Adaptive platform trial |
| Start date | 2020 |
RECOVERY (clinical trial) The Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial was an adaptive platform study launched in 2020 to evaluate treatments for severe acute respiratory syndrome coronavirus 2 during the COVID-19 pandemic. Designed and coordinated by investigators at the University of Oxford in collaboration with the National Health Service (United Kingdom), the trial produced high-profile results influencing practice at institutions such as World Health Organization, European Medicines Agency, National Institutes of Health, and national health services across United States, India, and Brazil.
The trial was established in response to the global health emergency declared by the World Health Organization and aligned with research efforts coordinated by organizations including the Wellcome Trust, Medical Research Council (United Kingdom), Nuffield Department of Medicine, University of Cambridge, and the Imperial College London. Objectives included rapid assessment of repurposed drugs and novel agents used in hospitals participating in networks such as the National Health Service (United Kingdom), NHS England, Public Health England, and academic centres like Addenbrooke's Hospital, Royal Liverpool University Hospital, and Guy's and St Thomas' NHS Foundation Trust. The protocol was informed by prior randomized trials exemplified by the Randomized Evaluation of COVID-19 Therapy model and by historic platform trials such as I-SPY 2 Trial, RECOVERY-Respiratory, and lessons from the Ebola virus epidemic in West Africa trials coordinated by WHO and Médecins Sans Frontières.
RECOVERY used an open-label, adaptive platform design modeled on randomized platform trials such as STAMPEDE and I-SPY 2 Trial, enabling multiple simultaneous comparisons within standard-of-care settings at sites like John Radcliffe Hospital and Addenbrooke's Hospital. The design incorporated centralized randomisation, pragmatic inclusion criteria applied in hospitals across United Kingdom regions including London, Manchester, Birmingham, and collection of outcome data linked to systems such as NHS Digital and registries like Office for National Statistics. Governance structures involved oversight by data monitoring committees akin to those in trials like SOLIDARITY Trial coordinated by World Health Organization and ethics review through bodies such as Health Research Authority (United Kingdom).
Interventions tested included corticosteroids and antiviral agents, with arms for drugs including dexamethasone, hydroxychloroquine, lopinavir–ritonavir, azithromycin, convalescent plasma, tocilizumab, colchicine, and monoclonal antibodies produced by firms linked to institutions like Roche, Regeneron, and Gilead Sciences. Randomisation was central and factorial in some comparisons, with allocation concealment and pragmatic implementation at wards in hospitals such as St Thomas' Hospital and Royal Infirmary of Edinburgh. The platform allowed addition and cessation of arms based on interim analyses, similar in principle to adaptations in I-SPY 2 Trial and STAMPEDE.
Primary outcome was all-cause mortality within 28 days, with secondary endpoints including time to hospital discharge, progression to invasive mechanical ventilation, and cause-specific mortality, assessed using linked datasets from NHS Digital and mortality registries like the Office for National Statistics. Statistical analysis employed intention-to-treat populations and frequentist interim monitoring by independent committees, drawing on methods used in large trials such as SOLIDARITY Trial and adaptive designs reported in NEJM and The Lancet. Pre-specified subgroup analyses referenced comorbid conditions recorded using classifications from NICE guidance and baseline severity scores used in intensive care units like Royal Brompton Hospital and Hammersmith Hospital.
RECOVERY's major early finding demonstrated that dexamethasone reduced 28-day mortality among patients receiving respiratory support, a result that influenced treatment guidelines by the World Health Organization, European Medicines Agency, and national bodies including NIH and NICE. The trial provided evidence against routine use of hydroxychloroquine and lopinavir–ritonavir, and contributed to evidence on azithromycin and convalescent plasma similar to findings from the SOLIDARITY Trial and trials by institutions such as Johns Hopkins University and Mount Sinai Health System. Policy and clinical practice in countries including United Kingdom, United States, India, South Africa, and Brazil adapted to RECOVERY results, and pharmaceutical regulators at FDA and EMA considered the data in emergency use authorizations and guidance.
Safety monitoring used routine hospital reporting and pharmacovigilance networks such as those operated by MHRA, VigiBase, and institutional adverse event committees at centres like Addenbrooke's Hospital. The trial reported expected adverse events associated with corticosteroids, immunomodulators like tocilizumab, and antivirals, with specific safety signals managed according to guidelines from EMA and WHO. Investigators collaborated with trials units and regulatory offices including the Clinical Trials Unit (University of Oxford) and Health Research Authority (United Kingdom) to report serious adverse events and amend protocols where necessary.
Criticism addressed open-label design, generalisability beyond United Kingdom hospital populations, and questions about subgroup power, echoing critiques made of platform trials such as SOLIDARITY Trial and adaptive studies like STAMPEDE. Limitations included pragmatic endpoints and reliance on routine data linkage rather than blinded adjudication used in trials at institutions like Mayo Clinic and Cleveland Clinic. Subsequent research built on RECOVERY via trials testing antiviral monoclonal antibodies by companies such as Regeneron and Gilead Sciences, immunomodulation studies at Imperial College London and multicentre collaborations including WHO SOLIDARITY efforts and national consortia funded by Wellcome Trust and NIHR.
Category:Clinical trials